Comments
The world has not had a new tuberculosis (TB) drug in about half a century, and then there were three. One of them, Pretomanid, was developed by non-profit organisation TB Alliance. Its President and CEO Dr Mel Spigelman gives us a peek into plans to make it more available, besides explaining why it is necessary to walk the fine line between medicine affordability and supply sustainability.
As part of a three drug regimen - Bedaquiline, pretomanid and linezolid , or BPaL as it is known, is recommended to treat highly drug-resistant forms of TB.
Follow The Hindu BusinessLine on Spotify
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.